Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 93.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 254,762 shares of the company's stock after acquiring an additional 123,230 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.42% of Health Catalyst worth $1,801,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Fred Alger Management LLC bought a new stake in shares of Health Catalyst in the 3rd quarter valued at approximately $6,858,000. Portolan Capital Management LLC bought a new stake in shares of Health Catalyst in the 3rd quarter valued at approximately $5,402,000. Raymond James Financial Inc. bought a new stake in shares of Health Catalyst in the 4th quarter valued at approximately $2,044,000. Martin & Co. Inc. TN grew its stake in shares of Health Catalyst by 80.0% in the 4th quarter. Martin & Co. Inc. TN now owns 490,998 shares of the company's stock valued at $3,471,000 after purchasing an additional 218,293 shares during the period. Finally, Point72 Asset Management L.P. grew its stake in shares of Health Catalyst by 69.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company's stock valued at $4,208,000 after purchasing an additional 211,805 shares during the period. 85.00% of the stock is currently owned by institutional investors.
Health Catalyst Trading Up 1.8 %
NASDAQ:HCAT traded up $0.08 during trading hours on Friday, hitting $4.41. 737,257 shares of the stock were exchanged, compared to its average volume of 601,548. The company's 50 day moving average is $5.16 and its two-hundred day moving average is $6.96. Health Catalyst, Inc. has a twelve month low of $3.76 and a twelve month high of $9.24. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $309.63 million, a P/E ratio of -3.27 and a beta of 1.41.
Analysts Set New Price Targets
HCAT has been the topic of several analyst reports. Stephens lowered their price objective on Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Thursday, March 6th. Wells Fargo & Company lowered their price objective on Health Catalyst from $13.00 to $10.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 21st. Citigroup reduced their target price on Health Catalyst from $10.50 to $10.00 and set a "buy" rating on the stock in a report on Friday, January 10th. Canaccord Genuity Group reduced their target price on Health Catalyst from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, January 21st. Finally, KeyCorp raised Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 target price on the stock in a report on Wednesday, January 8th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $9.27.
Get Our Latest Analysis on Health Catalyst
Insiders Place Their Bets
In other Health Catalyst news, Director Duncan Gallagher sold 4,500 shares of the company's stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $6.98, for a total transaction of $31,410.00. Following the transaction, the director now owns 74,438 shares of the company's stock, valued at approximately $519,577.24. This represents a 5.70 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Linda Llewelyn sold 6,442 shares of the company's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $5.80, for a total value of $37,363.60. Following the transaction, the insider now directly owns 92,260 shares in the company, valued at approximately $535,108. This represents a 6.53 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 65,530 shares of company stock valued at $362,167. 2.50% of the stock is currently owned by corporate insiders.
About Health Catalyst
(
Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Recommended Stories
Before you consider Health Catalyst, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.
While Health Catalyst currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
